Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Bristol Myers Squibb's experimental radiopharmaceutical RYZ101 significantly delayed disease progression in patients with rare, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that had worsened after prior treatment. The drug uses actinium-225 to deliver radioactive particles directly to tumor tissue. Full data haven't been released yet, but the company plans to discuss results with regulators and present them at a future medical meeting.
Bristol Myers Squibb's experimental cancer therapy RYZ101 has cleared a key hurdle, significantly delaying disease progression in patients with rare, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) — cancers arising in hormone-producing cells of the GI tract and pancreas. The late-stage trial tested RYZ101 against standard-of-care treatments in patients whose disease had already progressed after Lutetium-177-based therapy, a tough-to-treat population with limited options.
RYZ101 belongs to the fast-growing class of radiopharmaceutical therapies, which work by delivering radioactive particles directly to tumor tissue to destroy cancer cells. This drug uses actinium-225, an alpha-emitting isotope, which may offer more precise tumor kill compared to older beta-emitting agents. Bristol Myers acquired the therapy through its $4.1 billion purchase of RayzeBio.
Key Takeaways:
Why it matters: For patients with GEP-NETs who've exhausted standard options, RYZ101 could represent a meaningful new treatment avenue. The results also bolster confidence in the broader radiopharmaceutical space, where major players like AstraZeneca and Eli Lilly are racing to develop next-generation therapies.
